Lördag 26 April | 23:23:21 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-16 08:30 Bokslutskommuniké 2025
2025-11-03 08:30 Kvartalsrapport 2025-Q3
2025-08-29 08:30 Kvartalsrapport 2025-Q2
2025-05-30 N/A X-dag ordinarie utdelning IZAFE B 0.00 SEK
2025-05-28 N/A Årsstämma
2025-04-25 - Kvartalsrapport 2025-Q1
2025-02-14 - Bokslutskommuniké 2024
2024-11-01 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-31 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2024-05-30 - Årsstämma
2024-04-26 - Kvartalsrapport 2024-Q1
2024-02-09 - Bokslutskommuniké 2023
2023-12-21 - Extra Bolagsstämma 2024
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-04-06 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2023-04-05 - Årsstämma
2023-02-03 - Bokslutskommuniké 2022
2022-11-07 - Kvartalsrapport 2022-Q3
2022-10-05 - Extra Bolagsstämma 2022
2022-08-26 - Kvartalsrapport 2022-Q2
2022-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2022-06-14 - Årsstämma
2022-04-29 - Kvartalsrapport 2022-Q1
2022-02-18 - Bokslutskommuniké 2021
2021-11-29 - Kvartalsrapport 2021-Q3
2021-09-23 - Extra Bolagsstämma 2021
2021-08-30 - Kvartalsrapport 2021-Q2
2021-06-28 - Årsstämma
2021-06-15 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2021-04-29 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-17 - Kvartalsrapport 2020-Q2
2020-06-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2020-06-25 - Årsstämma
2020-05-11 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-05-10 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2019-05-06 - Kvartalsrapport 2019-Q1
2019-04-10 - Årsstämma
2019-02-28 - Bokslutskommuniké 2018
2018-12-18 - Extra Bolagsstämma 2018
2018-10-24 - Kvartalsrapport 2018-Q3
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2018-04-11 - Årsstämma
2018-03-22 - Bokslutskommuniké 2017
2017-08-29 - Kvartalsrapport 2017-Q2
2017-05-09 - Kvartalsrapport 2017-Q1
2017-04-26 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2017-04-25 - Årsstämma
2017-02-24 - Bokslutskommuniké 2016
2016-11-16 - Kvartalsrapport 2016-Q3
2016-10-19 - Extra Bolagsstämma 2016
2016-08-31 - Kvartalsrapport 2016-Q2
2016-04-20 - Kvartalsrapport 2016-Q1
2016-02-25 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2016-02-24 - Årsstämma
2016-02-04 - Bokslutskommuniké 2015
2015-11-13 - Kvartalsrapport 2015-Q3
2015-09-04 - Kvartalsrapport 2015-Q2
2015-07-22 - Extra Bolagsstämma 2015
2015-05-07 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2015-05-06 - Årsstämma
2015-04-17 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-12-17 - Extra Bolagsstämma 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-11-14 - Kvartalsrapport 2014-Q3
2014-08-29 - Kvartalsrapport 2014-Q2
2014-06-12 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2014-06-11 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-21 - Bokslutskommuniké 2013
2013-11-15 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-06-17 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2013-06-14 - Årsstämma
2013-05-17 - Kvartalsrapport 2013-Q1
2013-02-22 - Bokslutskommuniké 2012
2012-11-30 - Kvartalsrapport 2012-Q3
2012-07-31 - Kvartalsrapport 2012-Q2
2012-06-20 - X-dag ordinarie utdelning IZAFE B 0.00 SEK
2012-06-19 - Årsstämma
2012-04-20 - Kvartalsrapport 2012-Q1
2012-02-21 - Bokslutskommuniké 2011
2011-11-04 - Kvartalsrapport 2011-Q3
2011-08-12 - Kvartalsrapport 2011-Q2
2011-05-06 - Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
iZafe Group är ett Life Science-bolag inriktat på utveckling och marknadsföring av digitala medicinska lösningar för läkemedelshantering i hemmet. Bolaget erbjuder produkter som Dosell, en läkemedelsrobot, och SaaS-lösningen Pilloxa, en uppkopplad dosettask. Produkterna ämnar minska risken för felmedicinering. Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group har sitt huvudkontor i Stockholm.
2025-04-03 14:30:00

After an increase of billable Dosell units by 25% in January and an additional 9% in February, the number rose by another 12% in March. This is a clear indication that our strategy is working and that demand for our solution continues to grow.

At the same time, it’s important to emphasize that we are still in an early stage. Growth is occurring from relatively low levels, but the pace is exceptional. During the first quarter of 2025, we activated as many units delivering medication daily as we had over the entire first five years since the original version of Dosell was developed – a significant milestone.

Our business model now shows clear scalability, with more active Dosell units generating a growing stream of recurring revenue. We are entering a commercial breakthrough phase with record-high momentum, fueled by demand from both municipalities and international partners.

Sweden: More municipalities onboard – focus on long-term expansion
In March, three new municipalities began using Dosell. We also signed a direct procurement agreement with a municipality that, after completing a pilot, decided to fully transition to Dosell from a previously used solution. They highlight its simplicity, reliability, and the fact that doses are not locked if missed – giving both users greater independence and care services increased flexibility in scheduling.

Another municipality has launched a pilot under our structured “municipal package,” and we have several ongoing tenders within home care and LSS (disability services). Every week, we receive new inquiries – a clear signal of a shifting market where scalable, modern solutions are increasingly in demand.

At the same time, it is important to point out that volumes per municipality are still relatively low. Our focus moving forward is to support each municipality in identifying more users, increasing usage, and maximizing societal benefit. As the population ages, care must scale – and with digital tools like Dosell, we can ensure safe and high-quality care for more people without overburdening resources.

The Netherlands: Strong customer onboarding and launch of Dosell TV
In the Netherlands, we continue to meet our growth forecast. Our partner TCCN reports that their largest customer, MobileCare, delivered an additional 72 units in March. Interest is growing steadily, with more organizations joining the system each week.

In April, TCCN is launching the first broadcast of Dosell TV – a new platform to share knowledge, inspire, and support new organizations in getting started. It is a concrete step towards scaling implementation and building a vibrant user and partner community. In parallel, TCCN is also exhibiting Dosell at a major trade fair in the Netherlands in April – a key opportunity to reach new customers and further strengthen our market position.

Spain: Pharmacy network and strong role in Savioo Home
The launch of Dosell in Spain through the Savioo Home concept is now underway. Our partner has attended several trade fairs in Barcelona and France, where Dosell was presented as a central component for ensuring proper medication adherence at home.

Over 50 pharmacies have already expressed interest in adopting the concept and will soon receive promotional materials for in-store and window displays. This is only the beginning – these 50 pharmacies are the first wave in a network of 1,500 that our partner is actively working with. The ambition is high, and we see a serious, long-term effort that lays the foundation for success.

Expansion: Engaging new markets and new partners
We are currently in active discussions with new potential partners, both in existing and new geographies. Interest is coming from both public and private sectors, all recognizing the need for digital medication management. Our strategy remains clear: grow with the right partners – those with the drive and ability to scale.

To Our Shareholders – Why We Believe in Our Direction
iZafe Group is stronger than ever. We have a highly demanded solution, a growing customer network, and a proven business model. At the same time, we remain humble about the fact that we are still in a building phase – but something has clearly shifted.

We’ve set a new pace in the market, delivering more active units in one quarter than in our first five years combined – and this is just the beginning. With the momentum we’re experiencing, combined with our long-term strategy, our belief is stronger than ever: Dosell has the potential to become a cornerstone in the future of medication management.

Thank you for following our journey – and for your continued trust.